Cargando…

A review of anabolic therapies for osteoporosis

Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Nancy E, Kelman, Ariella
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC193734/
https://www.ncbi.nlm.nih.gov/pubmed/12932280
_version_ 1782120914569134080
author Lane, Nancy E
Kelman, Ariella
author_facet Lane, Nancy E
Kelman, Ariella
author_sort Lane, Nancy E
collection PubMed
description Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time.
format Text
id pubmed-193734
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1937342003-09-15 A review of anabolic therapies for osteoporosis Lane, Nancy E Kelman, Ariella Arthritis Res Ther Review Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time. BioMed Central 2003 2003-08-05 /pmc/articles/PMC193734/ /pubmed/12932280 Text en Copyright © 2003 BioMed Central Ltd
spellingShingle Review
Lane, Nancy E
Kelman, Ariella
A review of anabolic therapies for osteoporosis
title A review of anabolic therapies for osteoporosis
title_full A review of anabolic therapies for osteoporosis
title_fullStr A review of anabolic therapies for osteoporosis
title_full_unstemmed A review of anabolic therapies for osteoporosis
title_short A review of anabolic therapies for osteoporosis
title_sort review of anabolic therapies for osteoporosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC193734/
https://www.ncbi.nlm.nih.gov/pubmed/12932280
work_keys_str_mv AT lanenancye areviewofanabolictherapiesforosteoporosis
AT kelmanariella areviewofanabolictherapiesforosteoporosis
AT lanenancye reviewofanabolictherapiesforosteoporosis
AT kelmanariella reviewofanabolictherapiesforosteoporosis